IMV Inc: Clinical-Stage Immuno-Oncology Company Develops Therapies Based on DPX Technology for Cancer Treatment IMV Inc., a Canadian-based clinical-stage immuno-oncology company, has developed a portfolio of therapies that utilize DPX, its immune-educating technology platform for the treatment of solid and hematological cancers. The company's current lead drug candidate, maveropepimut-S, is a DPX-based immunotherapy that targets survivin-expressing cells in Phase II clinical trials for diseases such as diffuse large B cell lymphoma, ovarian cancer, bladder cancer, liver cancer, and MSI-H solid tumors. A Phase I clinical trial for the treatment of breast cancer is also underway. In addition, IMV Inc. is currently developing DPX-SurMAGE, which is in Phase I clinical trials for bladder cancer, as well as DPX-COVID-19 and DPX-RSV for the treatment of infectious diseases. IMV Inc. was founded in 2000 and was formerly known as Immunovaccine Inc. The company changed its name to IMV Inc. in May 2018 and is headquartered in Dartmouth, Canada.
Imv's ticker is IMV
The company's shares trade on the TSX stock exchange
They are based in Dartmouth, Nova Scotia
There are 51-200 employees working at Imv
It is imv-inc.com/about-us
Imv is in the Healthcare sector
Imv is in the Biotechnology industry
The following five companies are Imv's industry peers: